Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q1 2021 Results - Earnings Call Transcript
02:42pm, Thursday, 29'th Apr 2021
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q1 2021 Results - Earnings Call Transcript
Recap: Blueprint Medicines Q1 Earnings
08:01am, Thursday, 29'th Apr 2021
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were up 18.48% over the past year to ($1.72), which beat the
Blueprint Medicines Reports First Quarter 2021 Financial Results
07:00am, Thursday, 29'th Apr 2021
CAMBRIDGE, Mass., April 29, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the first quarter ended March 31, 2
Blueprint Medicines to Report First Quarter 2021 Financial Results on Thursday, April 29, 2021
08:00am, Thursday, 22'nd Apr 2021
CAMBRIDGE, Mass., April 22, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m.
3 Magic Formula Health Care Stock Picks
11:41am, Monday, 19'th Apr 2021
If you want to enhance your likelihood to beat the market, one method is to select stocks that rank highly according to the "Magic Formula" criteria.
1 Cancer Stock to Buy and Hold for the Next Decade
06:32am, Saturday, 17'th Apr 2021
Blueprint Medicines is setting itself up to become the leader in precision oncology.
Blueprint Medicines Data Highlight Clinical Leadership in Systemic Mastocytosis at AACR Annual Meeting 2021
02:00pm, Sunday, 11'th Apr 2021
CAMBRIDGE, Mass., April 11, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that multiple presentations across the company's leading systemic mastocytosis (SM) pro
Blueprint Medicines Presents Preclinical Data Highlighting Broad Precision Therapy Research Pipeline at AACR Annual Meeting 2021
08:30am, Saturday, 10'th Apr 2021
CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced data from multiple poster presentations highlighting the breadth of the company's precis
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Wednesday, 07'th Apr 2021
CAMBRIDGE, Mass., April 7, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunothera
CAMBRIDGE, Mass., April 5, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:00 a.m.
Blueprint Medicines (BPMC) Up 2.1% Since Last Earnings Report: Can It Continue?
12:40pm, Friday, 19'th Mar 2021
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?
Blueprint Medicines to Showcase Scientific Leadership in Precision Oncology and Hematology at AACR Annual Meeting 2021
04:30pm, Wednesday, 10'th Mar 2021
CAMBRIDGE, Mass., March 10, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new data for multiple research- and clinical-stage programs across the
Blueprint Medicines (BPMC) Gets EMA Validation for Ayvakyt in SM
10:39am, Thursday, 04'th Mar 2021
The EMA validates Blueprint Medicines' (BPMC) Type II variation marketing authorization application for Ayvakyt to treat advanced systemic mastocytosis.
Blueprint Medicines (BPMC) Q4 Earnings Beat, Revenues In Line
11:21am, Thursday, 18'th Feb 2021
Blueprint Medicines' (BPMC) earnings beat estimates in the fourth quarter of 2020 while revenues meet the same. Shares up.
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q4 2020 Results - Earnings Call Transcript
12:23pm, Wednesday, 17'th Feb 2021
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q4 2020 Results - Earnings Call Transcript
